Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Fostamatinib

46f8db8b-2977-5961-89f1-521acc7af1c8 · FDA Approved · targets SYK

Fostamatinib

MeasuredReference

Fostamatinib targets NEK9, EGFR, FLT3. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

NEK9EGFRFLT3AURORA_AROS_ROS1

Top hallmarks

  • tumor promoting inflammation5.6k
  • proliferation4.1k
  • evading apoptosis3.8k

Top pathways disrupted

  • apical junction10.5k
  • pi3k akt mtor signaling9.4k
  • allograft rejection9.2k

Resistance landscape — Fostamatinib

MeasuredReference

10 known oncogenic variants exist on Fostamatinib's top targets — see detail for inhibition impact.

Open in new tab